Key Duchenne Muscular Dystrophy Treatment Market Players:
- Sarepta Therapeutics, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- NS Pharma, Inc.
- PTC Therapeutics, Inc.
- Santhera Pharmaceuticals
- Solid Biosciences Inc.
- Edgewise Therapeutics, Inc.
- Catabasis Pharmaceuticals
- FibroGen, Inc.
- Italfarmaco S.p.A.
- BioMarin Pharmaceutical Inc.
- Dyne Therapeutics, Inc.
- Roche Holding AG
- Genethon
- Wave Life Sciences
- NS Pharma, Inc.
- Daiichi Sankyo Company, Limited
- Taisho Pharmaceutical Holdings
- Takeda Pharmaceutical Company Limited
- JCR Pharmaceuticals Co., Ltd.
The duchenne muscular dystrophy treatment market is led by the heavy competition among key players, including Sarepta, Pfizer, and Roche, who collectively control the global revenue. Their focus on gene therapies and exon-skipping drugs, coupled with strategic collaborations and manufacturing capacity expansion, is highlighting the major opportunity present in this sector. On the other hand, emerging innovators, such as Wave Life Sciences and CRISPR Therapeutics. The current dynamics of this merchandise are shaped by accelerating participation of APAC, advancements in clinical trials, and expedited regulatory approvals.
Below is the list of some prominent players operating in the global market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of the duchenne muscular dystrophy treatment market was over USD 1.9 million.
The market size for the duchenne muscular dystrophy treatment market size was over USD 1.9 million in 2025 and is estimated to reach USD 6.2 million by the end of 2035, expanding at a CAGR of 12.8% during the forecast timeline, i.e., 2026-2035.
The major players in the market are Sarepta Therapeutics, Pfizer, Roche, Solid Biosciences, Santhera Pharmaceuticals, Wave Life Sciences, Italfarmaco, and others.
In terms of distribution channel, hospital pharmacies dominate the segment and are expected to have the revenue share of 65.5%.
The market in North America is anticipated to attain the largest share of 42.2% in the duchenne muscular dystrophy treatment market throughout the analyzed timeframe.
